Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: A case series

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

“…Singh and Lebwohl conducted a retrospective chart review in 8 patients (stage IA-IIB) with CTCL that had recurred following monotherapy with various agents, including TSEB, IFN-a, PUVA and topical steroids: the patients were then treated with PUVA plus bexarotene. 115 A response was achieved in all 8 patients, including 5 CRs. 115 An EORTC-sponsored phase III trial is currently recruiting patients for a comparison between PUVA alone and PUVA plus bexarotene.…”

“…115 A response was achieved in all 8 patients, including 5 CRs. 115 An EORTC-sponsored phase III trial is currently recruiting patients for a comparison between PUVA alone and PUVA plus bexarotene. 116 Recommendations for second-line treatment of MF (stages IA, IB and IIA) are summarised in Table 5. 12.3.…”

Immunopathogenesis and therapy of cutaneous T cell lymphoma

“…For patients who do not yet manifest overt peripheral blood disease but who exhibit more extensively infiltrated cutaneous plaques on a greater skin surface area, combined therapeutic approaches appear to result in more rapid responses (65)(66)(67)(68). IFN-α, produced by plasmacytoid DCs, is a product of the innate immune response, and appears to be one of the most highly active biologic agents used in the therapy of MF/SS (69).…”

The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma

“…In patients with MF stage IA-IIB, combination of low-dose bexarotene (75 mg per day) with PUVA led to clinical response in all patients with CR seen in 63% of patients. 44 In a prospective study of 14 patients with relapsed or treatmentrefractory MF (stage IA-III), patients were treated with bexarotene at 150 to 300 mg per day concurrently with PUVA. Overall response rate was 67%, with 29% CRs.…”